Mease, Philip J https://orcid.org/0000-0002-6620-0457
Landewé, Robert https://orcid.org/0000-0002-0577-6620
Rahman, Proton
Tahir, Hasan
Singhal, Atul
Boettcher, Elke
Navarra, Sandra
Readie, Aimee
Mpofu, Shephard
Delicha, Eumorphia Maria
Pricop, Luminita
van der Heijde, Desirée https://orcid.org/0000-0002-5781-158X
Clinical trials referenced in this document:
Documents that mention this clinical trial
POS1016 RELATIONSHIPS BETWEEN DISEASE DURATION AND RADIOGRAPHIC PROGRESSION AMONG PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB IN FUTURE 5
https://doi.org/10.1136/annrheumdis-2022-eular.278
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00652-7
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
https://doi.org/10.1136/rmdopen-2022-002939
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study (Results)
https://doi.org/10.1136/annrheumdis-2017-212687
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study
https://doi.org/10.1136/rmdopen-2021-001600
POS1050 SECUKINUMAB LEADS TO IMPROVEMENT ACROSS PSORIATIC ARTHRITIS MANIFESTATIONS OVER 2 YEARS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR: A POST HOC ANALYSIS OF FUTURE 5
https://doi.org/10.1136/annrheumdis-2021-eular.1862
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2021-001845
POS1051 SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND INHIBITS STRUCTURAL DAMAGE IN PsA PATIENTS WITH SUSTAINED REMISSION OR LOW DISEASE ACTIVITY: RESULTS FROM A PHASE 3 STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1971
THU0373 SECUKINUMAB DOSE ESCALATION ON ACR RESPONSES IN ANTI-TUMOUR NECROSIS FACTOR NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 FUTURE 4 AND FUTURE 5 STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.287
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
POS0972 RELATIONSHIPS BETWEEN INHIBITION OF RADIOGRAPHIC PROGRESSION AND ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION AND THEIR CORE COMPONENTS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB OVER 2 YEARS IN FUTURE 5
https://doi.org/10.1136/annrheumdis-2024-eular.497